In this context, using 5-ASA to prevent the re-expression of LGR5 may not only prevent tumour formation and potentially recurrence after treatment but may also improve the efficacy of conventional therapies, improving the prognosis of patients with CRC. This evidence concerns the gene LGR5 and neoplasm.